ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine

Wspolczesna Onkologia

Volumn 19, Issue 3, 2015, Pages 207-213

  Ulker, Mehmet ^a   Duman, Berna Bozkurt ^a   Sahin, Berksoy ^a   Gumurdulu, Derya ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

ERRC1; Lung cancer; Ovarian cancer; Pancreatic cancer; Prognostic factors; RRM1

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; PLATINUM; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVARY CARCINOMA; PANCREAS CARCINOMA; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TISSUE SECTION; TREATMENT RESPONSE;

EID: 84936773034     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2015.52656     Document Type: Article

References (24)

1. Akita H, Zheng Z, Takeda Y., et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009; 28: 2903-9.
2. Bepler G, Kusmartseva I, Sharma S., Gautam A, Cantor A, Sharma A., Simon G. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4731-7.
3. Bergman AM, Eijk P P, Ruiz van Haperen VW, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005; 65: 9510-6.
4. Booton R, Ward T, Ashcroft L., Morris J, Heighway J, Thatcher N. ERRC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Clin Oncol 2007; 2: 902-6.
5. Codegoni AM, Broggini M, Pitelli M.R., Pantarotto M., Torri V, Mangioni C, D'Incalci M. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 1997; 65: 130-7.
6. Davidson JD, Ma L, Flagella M., Geeganage S, Gelbert LM, Slapak CA An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-smallcell lung cancer cell lines. Cancer Res 2004; 64: 3761-6.
7. Eisenhauer EA, Therasse P, Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
8. Furuta T, Ueda T, Aune G., Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as determinant of cisplatin sensitivity of human cells. Cancer Res 2002; 62: 4899-902.
9. Ferrandina G, Mey V, Nannizzi S., et al. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Cancer Chemother Pharmacol 2010; 65: 679-86.
10. Heinemann V, Xu YZ, Chubb S, Sen A., Hertel LW, Grindey GB, Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol 1990; 38: 567-72.
11. Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucette S., Antoniouk O, Goss G, Dimitroulakos J. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 2009; 124: 806-15.
12. Lord RV, Brabender J, Gandara D., et al. Low level ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-91.
13. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu J.J., Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94: 703-8.
14. Mini E, Nobili S, Caciagli B., Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17 (Suppl 5): 7-12.
15. Olaussen KA, Dunant A, Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-91.
16. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535-42.
17. Kim R, Tan A, Lai K.K., Jiang J., Wang Y, Rybicki LA, Liu X. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer 2011; 117: 3126-34.
18. Richardson A, Kaye SB Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updat 2005; 8: 311-21.
19. Rosell R, Felip E, Taron M., et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small-cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004; 10 (12 Pt 2): 4215-9.
20. Maithel SK, Coban I, Kneuertz P.J., et al. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection. Ann Surg Oncol 2011; 18: 2699-705.
21. Scheil-Bertram S., Tylus-Schaaf P, du Bois A, Harter P, Oppitz M., Ewald-Riegler N, Fisseler-Eckhoff A. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. Gynecol Oncol 2010; 119: 325-31.
22. Mojgan H, Massoud H, Ahmad E. ERCC1 intron 1 was associated with breast cancer risk. Arch Med Sci 2012; 8: 655-8.
23. Eisenhauer EA, Therasse P, Bogaerts J., et al. New response evaluation criteria in solid tumors: revised RECIST guideline (verion 1.1). Eur J Cancer 2009; 45: 228-47.
24. Eldeeb H, Reza S. Northampton outcome for first and second line chemotherapy in non small cell lung cancer: 5 years data. Contemp Oncol (Pozn) 2012; 16: 420-3.